Subscribe to our Newsletters !!
There is one fact about life on Earth we cannot es
In this application note, we demonstrate how the C
The Nobel Prize in Physiology or Medicine awarded
In today’s rapidly evolving bioprocessing landsc
Alembic Pharmaceutica
Tofu has been a favorite food for vegetarians and
Dear Readers, Welcome to the latest issue of Mi
Glenmark Pharmaceuticals on Monday said its US arm has received tentative approval from the country’s health regulator for its generic Regadenoson injection. Regadenoson injection is given during the preparation for a radiologic examination of blood flow through the heart to test for coronary artery disease.
According to a statement, the tentative approval was granted by the United States Food & Drug Administration to Glenmark Pharmaceuticals Inc., USA (Glenmark). It is for Regadenoson Injection at 0.4 mg/5 mL (0.08 mL) Single-Dose Prefilled Syringe. It is the generic Lexiscan injection at 0.4 mg/5mL (0.08 mg/mL) of Astellas US Inc.
The company cited IQVIATM sales data from the 12-month period ending November 2021 and stated that the Lexiscan(r), 0.4 mg/5 mL (0.08mg/mL) market had achieved an annual sales figure of around USD 659.9 millions. According to the company, its current portfolio includes 172 products that are authorized for distribution in the US market and 47 abbreviated drug applications (ANDAs), which are awaiting approval by the USFDA.
